Announcements Trials
Browse Landscape

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2929Neoplasms 2624Lung Neoplasms 1366Colorectal Neoplasms 1328Prostatic Neoplasms 1214Carcinoma, Non-Small-Cell Lung 1079Carcinoma, Hepatocellular 782Stomach Neoplasms 720Pancreatic Neoplasms 701Ovarian Neoplasms 586Colonic Neoplasms 533Uterine Cervical Neoplasms 497Head and Neck Neoplasms 495Rectal Neoplasms 472Melanoma 467Multiple Myeloma 463Esophageal Neoplasms 422Neoplasm Metastasis 418Brain Neoplasms 404Lymphoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 397Urinary Bladder Neoplasms 386Leukemia, Myeloid, Acute 385Leukemia 339Carcinoma, Renal Cell 329Liver Neoplasms 320Endometrial Neoplasms 319Hematologic Neoplasms 312Recurrence 298Disease 272

Interventions

Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × HER2+ Breast Cancer × Clear all
NCT06537674 2024-08-05

Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

Jiangsu Famous Medical Technology Co., Ltd.

Not yet recruiting
100 enrolled
Breast

HER2+ Breast Cancer

NCT05931042 2023-07-05

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

Rawalpindi Medical College

Completed
1,209 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡